FEACYP
FEACYP is a thioredoxin reductase (TrxR) inhibitor. FEACYP inhibits thioredoxin reductase activity, induces ROS by increasing basal cellular hydrogen peroxide production, suppresses tumor growth, exerts cytotoxicity against human cancer cells, and exhibits antiproliferative activity in human pancreatic cancer 3D spheroids. FEACYP can be used in the research of ovarian cancer, colon cancer, pancreatic cancer, and lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C27H37F3Fe2N4O5PS
- Masse moléculaire:729.33
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
FEACYP (compound 2a) (72 h) potently inhibits the viability of 2008, HCT-15, PSN-1, and U1285 human cancer cells with IC50 values ranging from 2.6-4.3 μM, and is 6.2-fold more selective for cancer cells than noncancerous HEK293 cells[1].
FEACYP (72 h) inhibits Cisplatin (HY-17394)-resistant C13* human ovarian adenocarcinoma cells with an IC50 of 7.3 μM[1].
FEACYP (72 h) potently inhibits the viability of 3D PSN-1 human pancreatic cancer spheroids with an IC50 of 16.2 μM[1].
FEACYP (5 μM; 24 h) inhibits thioredoxin reductase activity in PSN-1 human pancreatic cancer cells by 52%, matching the inhibitory capacity of Auranofin (HY-B1123)[1].
FEACYP induces a time-dependent increase in reactive oxygen species production in PSN-1 human pancreatic cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8 weeks, 24±3 g, Female C57BL/6 mice (LLC cells) [1]
-
Dosage:8 mg/kg
-
Administration:I.p.; daily for 15 days
-
Result:Reduced the average tumor growth by 88% with less body weight loss pronounced (∼12%).
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- ROS/oxidative-stress fluorescent staining
- Patient-Derived Xenograft (PDX)
- Patient-Derived Orthotopic Xenograft (PDOX)
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
Masse moléculaire 729.33
-
Formule C27H37F3Fe2N4O5PS
-
SMILES
C[n](C1CCCCC1)[c+]2[Fe]3([P@]4(CN5C6)CN(C5)CN6C4)([])[Fe]2(C3=O)(C=O)[].[O-]S(=O)(C(F)(F)F)=O.c7cccc7.c8cccc8
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FEACYP Related Classifications
HY-161811 Related Classifications
Powered by Bioz